(Q39926646)

15 September 2017

title

Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis (English)

1 reference

15 September 2017

Yaowei Zhu

3

0 references

author name string

Honghui Zhou

1

1 reference

15 September 2017

Chuanpu Hu

2

1 reference

15 September 2017

Ming Lu

4

1 reference

15 September 2017

Sam Liao

5

1 reference

15 September 2017

Newman Yeilding

6

1 reference

15 September 2017

Hugh M Davis

7

1 reference

15 September 2017

language of work or name

1 reference

23 November 2009

1 reference

The Journal of Clinical Pharmacology

15 September 2017

published in

1 reference

15 September 2017

volume

50

1 reference

15 September 2017

issue

3

1 reference

15 September 2017

page(s)

257-267

1 reference

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

Epidemiology of psoriasis: clinical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

21 January 2018

Psoriasis comorbidities

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

New biologics for psoriasis and psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

Impact of censoring data below an arbitrary quantification limit on structural model misspecification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343695

21 January 2018

Identifiers

DOI

10.1177/0091270009343695

1 reference

15 September 2017

1 reference